China’s KeXing New Crown vaccine has been involved in a number of medical incidents in Hong Kong over the past few days, while another domestic New Crown vaccine, developed by Sinopharm, has been suspected of misinformation during a phase III clinical trial in Peru. Local media reported that the vaccine was only 11.5% effective, giving China, which is promoting vaccine diplomacy, a bruising blow, and domestic media confirmed that they received a stern warning not to reproduce any negative information about the domestic New Crown vaccine.
The Peruvian media revealed last week that the phase III clinical trial results of the Sinopharm Wuhan Xinguan vaccine in Peru showed an effective rate of 33%, but the effective rate of the Sinopharm Beijing vaccine was only 11.5%. This is not only far below the previously announced Chinese official effectiveness rate of nearly 80%, but also far below the minimum threshold of more than half effectiveness required by the World health Organization.
Sinopharm issued a statement on Saturday (6), saying that the Peruvian media had been misinformed and that it would reserve the right to pursue responsibility.
Ms. Zhu, a front-line worker in China’s Epidemic prevention, pointed out to the station that it is almost an open secret that the effectiveness of domestic vaccines is being questioned, only that no one can say anything about it. Even within the Chinese CDC system, half of the population refuses to receive the domestic New Crown vaccine. She reminded that older people or those with underlying diseases are not recommended to receive the domestic vaccine.
Miss Zhu said: older people are advised not to fight, no underlying disease is still better, with underlying disease, it is not recommended to fight. And you see the CDC, half of them did not play. There is no parameter to refer to. And it seems to be valid for a few months, it is not a lifetime, half a year later it will expire, there is no point. It is quite a tangle, this problem. The doctor, in fact, also let you make your own decision, he will not say you can play or not to play. It’s a psychological comfort, I’ll tell you.
Ren Ruihong, the former head of the Chinese Red Cross’s major disease relief program, pointed out that the Phase III clinical trial data of the Sinopharm vaccine was bad, which was entirely expected. She pointed out that because the clinical data has not been made public so far, the effectiveness of the domestic vaccine itself is doubtful, plus the inactivated vaccine of Sinopharm is developed with the earliest strain, and its effectiveness itself will be rapidly weakened with the large number of virus variants.
Ren Ruihong said: Inactivated vaccines are now the most done in China, with the most started strains. So it is basically no resistance to this variant of the virus. The efficiency of this has always been a very controversial issue, but its efficiency is very low, this is known to everyone. The latest study says that Pfizer’s, if it has a variant, it is slightly adjusted, and then the third or fourth injection, can completely resist the variant of the virus. But inactivated vaccines, including adenovirus vaccines, will have significantly reduced protection against this variant of the virus.
Our correspondent has called Sinopharm several times, but the agency’s phone number has been unavailable.
The Peruvian Ministry of Health defended Sinopharm, repeating that Chinese officials had previously announced the results of a trial in the United Arab Emirates with an efficiency rate of 79.34%, but did not release information about the vaccine trial in Peru, as a central media reporter revealed that Beijing is pushing forward with vaccine diplomacy in third world countries, and any negative news related to the vaccine is very sensitive. The domestic media has been warned not to report any negative information about the domestic vaccine.
Since the outbreak and spread of the New Crown epidemic in Wuhan early last year, Chinese officials have been engaged in a national race for a New Crown vaccine. But with the successful development of vaccines in advanced countries and China’s own short supply of vaccines, the Chinese government is once again pushing vaccine diplomacy, but with little success and at high cost.
Recent Comments